Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.48 |
| ▸ | CTSD | P07339 | 2/20 | 0.48 |
| ▸ | FNTA | P49354 | 9/20 | 0.46 |
| ▸ | FNTB | P49356 | 9/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619350 | 0.91 | BACE1 (0.45) | BACE1CTSDFNTAFNTBFOLH1 | |
| SCHEMBL30053022 | 0.91 | FNTA (0.50) | BACE1CTSDFNTAFNTBPGGT1B | |
| SCHEMBL31341136 | 0.90 | BACE1 (0.53) | BACE1CTSDBACE2 | |
| SCHEMBL30051583 | 0.90 | FOLH1 (0.51) | BACE1CTSDFNTAFNTBFOLH1 | |
| SCHEMBL30052925 | 0.90 | BACE1 (0.48) | BACE1CTSDFNTAFNTBFOLH1 | |
| SCHEMBL30051536 | 0.89 | FOLH1 (0.56) | FNTAFNTBFOLH1PGGT1BCTSB | |
| SCHEMBL11668382 | 0.89 | FNTA (0.47) | FNTAFNTBPGGT1B | |
| SCHEMBL30262888 | 0.89 | FNTA (0.52) | BACE1CTSDFNTAFNTBFOLH1 | |
| SCHEMBL30053260 | 0.89 | FOLH1 (0.42) | BACE1CTSDFNTAFNTBFOLH1 | |
| SCHEMBL29527825 | 0.88 | FNTA (0.46) | BACE1CTSDFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | BACE1 252/4885CTSD 503/4885FNTA 734/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | BACE1 588/4885CTSD 213/4885FNTA 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.